In Vitro Comparison of the Effects of Imatinib and Ponatinib on Chronic Myeloid Leukemia Progenitor/Stem Cell Features

Researchers compared the effects of tyrosine kinase inhibitors belonging to different generations, imatinib and ponatinib, on progenitor/stem cell expansion potential and markers.
[Targeted Oncology]
Tusa, I., Cheloni, G., Poteti, M., Silvano, A., Tubita, A., Lombardi, Z., Gozzini, A., Caporale, R., Scappini, B., Dello Sbarba, P., & Rovida, E. (2020). In Vitro Comparison of the Effects of Imatinib and Ponatinib on Chronic Myeloid Leukemia Progenitor/Stem Cell Features. Targeted Oncology. https://doi.org/10.1007/s11523-020-00741-x Cite
Full Article

Continue readingIn Vitro Comparison of the Effects of Imatinib and Ponatinib on Chronic Myeloid Leukemia Progenitor/Stem Cell Features”

Bookmark

No account yet? Register

0
Share

A Novel Approach to Genetic Engineering of T-Cell Subsets by Hematopoietic Stem Cell Infection with a Bicistronic Lentivirus

Designed novel lentiviral constructs harbored a global promoter regulating mCherry for hematopoietic stem cell selection and a T-cell specific promoter upstream of eGFP.
[Scientific Reports]
Bogert, N. V., Furkel, J., Din, S., Braren, I., Eckstein, V., Müller, J. A., Uhlmann, L., Katus, H. A., & Konstandin, M. H. (2020). A novel approach to genetic engineering of T-cell subsets by hematopoietic stem cell infection with a bicistronic lentivirus. Scientific Reports, 10(1), 13740. https://doi.org/10.1038/s41598-020-70793-6 Cite
Full Article

Continue reading “A Novel Approach to Genetic Engineering of T-Cell Subsets by Hematopoietic Stem Cell Infection with a Bicistronic Lentivirus”

Bookmark

No account yet? Register

0
Share

Autologous Hematopoietic Stem Cell Transplantation for Refractory Stiff-Person Syndrome: The UK Experience

Autologous hematopoietic stem cell transplantation was an intensive but well tolerated and effective treatment option for patients with Stiff Person Syndrome refractory to conventional immunotherapy.
[Journal of Neurology]
Kass-Iliyya, L., Snowden, J. A., Thorpe, A., Jessop, H., Chantry, A. D., Sarrigiannis, P. G., Hadjivassiliou, M., & Sharrack, B. (2020). Autologous haematopoietic stem cell transplantation for refractory stiff-person syndrome: the UK experience. Journal of Neurology. https://doi.org/10.1007/s00415-020-10054-8 Cite
Full Article

Continue reading “Autologous Hematopoietic Stem Cell Transplantation for Refractory Stiff-Person Syndrome: The UK Experience”

Bookmark

No account yet? Register

0
Share

A Novel Approach to Genetic Engineering of T-Cell Subsets by Hematopoietic Stem Cell Infection with a Bicistronic Lentivirus

Two T-cell specific promoters were assessed: the distal Lck—and the CD3δ-promoter. Transduced hematopoietic stem cells were FACS sorted by mCherry expression and transferred into sublethally irradiated C57/BL6 mice.
[Scientific Reports]
Bogert, N. V., Furkel, J., Din, S., Braren, I., Eckstein, V., Müller, J. A., Uhlmann, L., Katus, H. A., & Konstandin, M. H. (2020). A novel approach to genetic engineering of T-cell subsets by hematopoietic stem cell infection with a bicistronic lentivirus. Scientific Reports, 10(1), 13740. https://doi.org/10.1038/s41598-020-70793-6 Cite
Full Article

Continue reading “A Novel Approach to Genetic Engineering of T-Cell Subsets by Hematopoietic Stem Cell Infection with a Bicistronic Lentivirus”

Bookmark

No account yet? Register

0
Share

Group 2 Innate Lymphoid Cells Must Partner with the Myeloid–Macrophage Lineage for Long-Term Postviral Lung Disease

Scientists used a mouse model that applied an improved genetic definition of ILC2s via IL-7r–conditional Rora gene targeting and took advantage of a distinct progression from acute illness to chronic disease, based on a persistent type 2 immune response to respiratory infection with a natural pathogen.
[Journal of Immunology]
Wu, K., Wang, X., Keeler, S. P., Gerovac, B. J., Agapov, E. V., Byers, D. E., Gilfillan, S., Colonna, M., Zhang, Y., & Holtzman, M. J. (2020). Group 2 Innate Lymphoid Cells Must Partner with the Myeloid–Macrophage Lineage for Long-Term Postviral Lung Disease. The Journal of Immunology, 205(4), 1084–1101. https://doi.org/10.4049/jimmunol.2000181 Cite
AbstractGraphical Abstract

Continue reading “Group 2 Innate Lymphoid Cells Must Partner with the Myeloid–Macrophage Lineage for Long-Term Postviral Lung Disease”

Bookmark

No account yet? Register

0
Share

COVID-19 Severity Associates with Pulmonary Redistribution of CD1c+ DC and Inflammatory Transitional and Nonclassical Monocytes

Investigators studied the frequencies and activation profiles of dendritic cells and monocytes present in the blood and lung of COVID-19 patients with different clinical severity in comparison with healthy individuals.
[Journal of Clinical Investigation]
Sánchez-Cerrillo, I., Landete, P., Aldave, B., Sánchez-Alonso, S., Sánchez-Azofra, A., Marcos-Jiménez, A., Ávalos, E., Alcaraz-Serna, A., Santos, I. de los, Mateu-Albero, T., Esparcia, L., López-Sanz, C., Martínez-Fleta, P., Gabrie, L., Guerola, L. del C., Fuente, H. de la, Calzada, M. J., González-Álvaro, I., Alfranca, A., … Martín-Gayo, E. (2020). COVID-19 severity associates with pulmonary redistribution of CD1c+ DC and inflammatory transitional and nonclassical monocytes. The Journal of Clinical Investigation. https://doi.org/10.1172/JCI140335 Cite
AbstractFull Article

Continue reading “COVID-19 Severity Associates with Pulmonary Redistribution of CD1c+ DC and Inflammatory Transitional and Nonclassical Monocytes”

Bookmark

No account yet? Register

0
Share

Resolving Fates and Single-Cell Transcriptomes of Hematopoietic Stem Cell Clones by PolyloxExpress Barcoding

Scientists found that differentiation-inactive, multilineage, and lineage-restricted hematopoietic stem cell clones reside in distinct regions of the transcriptional landscape of hematopoiesis.
[Cell Stem Cell]
Pei, W., Shang, F., Wang, X., Fanti, A.-K., Greco, A., Busch, K., Klapproth, K., Zhang, Q., Quedenau, C., Sauer, S., Feyerabend, T. B., Höfer, T., & Rodewald, H.-R. (2020). Resolving Fates and Single-Cell Transcriptomes of Hematopoietic Stem Cell Clones by PolyloxExpress Barcoding. Cell Stem Cell, 0(0). https://doi.org/10.1016/j.stem.2020.07.018 Cite
AbstractGraphical Abstract

Continue reading “Resolving Fates and Single-Cell Transcriptomes of Hematopoietic Stem Cell Clones by PolyloxExpress Barcoding”

Bookmark

No account yet? Register

0
Share

Targeted Gene Correction of Human Hematopoietic Stem Cells for the Treatment of Wiskott – Aldrich Syndrome

The authors showed that a CRISPR/Cas9-based genome editing strategy allowed the precise correction of Wiskott-Aldrich syndrome mutations in up to 60% of human hematopoietic stem and progenitor cells, without impairing cell viability and differentiation potential.
[Nature Communications]
Rai, R., Romito, M., Rivers, E., Turchiano, G., Blattner, G., Vetharoy, W., Ladon, D., Andrieux, G., Zhang, F., Zinicola, M., Leon-Rico, D., Santilli, G., Thrasher, A. J., & Cavazza, A. (2020). Targeted gene correction of human hematopoietic stem cells for the treatment of Wiskott - Aldrich Syndrome. Nature Communications, 11(1), 4034. https://doi.org/10.1038/s41467-020-17626-2 Cite
Full Article

Continue reading “Targeted Gene Correction of Human Hematopoietic Stem Cells for the Treatment of Wiskott – Aldrich Syndrome”

Bookmark

No account yet? Register

0
Share

Unrelated Cord Blood Transplantation with Myeloablative Conditioning for Pediatric Acute Lymphoblastic Leukemia in Remission: Prognostic Factors

In the total patient cohort, five-year leukemia-free survival and overall survival rates after unrelated cord blood transplantation were 61.1% and 67.7%, respectively.
[Bone Marrow Transplantation]
Abstract

Continue reading “Unrelated Cord Blood Transplantation with Myeloablative Conditioning for Pediatric Acute Lymphoblastic Leukemia in Remission: Prognostic Factors”

Bookmark

No account yet? Register

0
Share

Hemogenyx Partners with UPenn to Study CAR T-Cell Therapy in AML

Hemogenyx Pharmaceuticals has inked a research agreement with the University of Pennsylvania (UPenn) for its CAR T-cell therapy for acute myeloid leukemia (AML).
[Hemogenyx Pharmaceuticals (Precision Oncology News)]
Press Release

Continue reading “Hemogenyx Partners with UPenn to Study CAR T-Cell Therapy in AML”

Bookmark

No account yet? Register

0
Share

Celyad to Begin Phase I Trial of Donor-Derived CAR T-Cell Therapy for Multiple Myeloma

Celyad Oncology SA announced that the company’s Investigational New Drug (IND) application for CYAD-211, the company’s first-in-class short hairpin RNA-based allogeneic CAR T candidate and second non-gene edited off-the-shelf program, is in effect with the FDA.
[Celyad Oncology SA]
Press Release

Continue reading “Celyad to Begin Phase I Trial of Donor-Derived CAR T-Cell Therapy for Multiple Myeloma”

Bookmark

No account yet? Register

0
Share
Share